These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33394321)

  • 61. Large variations in risk of hepatocellular carcinoma and mortality in treatment naïve hepatitis B patients: systematic review with meta-analyses.
    Thiele M; Gluud LL; Fialla AD; Dahl EK; Krag A
    PLoS One; 2014; 9(9):e107177. PubMed ID: 25225801
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
    Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
    J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area.
    Ungtrakul T; Mahidol C; Chun-On P; Laohapand C; Siripongsakun S; Worakitsitisatorn A; Vidhayakorn S; Boonchuay W; Dechma J; Sornsamdang G; Soonklang K; Sriprayoon T; Tanwandee T; Auewarakul CU
    World J Gastroenterol; 2016 Sep; 22(34):7806-12. PubMed ID: 27678364
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B.
    Jeon MY; Kim BK; Lee JS; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Kim SU
    Clin Mol Hepatol; 2021 Apr; 27(2):295-304. PubMed ID: 33317247
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Risk factors for the development of liver cancer in patients with hepatitis B-related liver cirrhosis treated with long-term nucleos(t)ide analogues].
    Zang WW; Su MH; Ling XZ; Wang RM; Cao BC; Wu YL; Deng DL; Wei HL; Liang XS; Jiang JN
    Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):679-685. PubMed ID: 32911907
    [No Abstract]   [Full Text] [Related]  

  • 68. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
    Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
    BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
    Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
    Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.
    Gordon SC; Lamerato LE; Rupp LB; Li J; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Vijayadeva V; Boscarino JA; Henkle EM; Oja-Tebbe N; Lu M;
    Clin Gastroenterol Hepatol; 2014 May; 12(5):885-93. PubMed ID: 24107395
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Chronic hepatitis B virus infection in Asian countries.
    Merican I; Guan R; Amarapuka D; Alexander MJ; Chutaputti A; Chien RN; Hasnian SS; Leung N; Lesmana L; Phiet PH; Sjalfoellah Noer HM; Sollano J; Sun HS; Xu DZ
    J Gastroenterol Hepatol; 2000 Dec; 15(12):1356-61. PubMed ID: 11197043
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
    Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
    Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Nikolopoulou G; Raptopoulou-Gigi M; Gogos C; Vafiadis-Zouboulis I; Karamanolis D; Chouta A; Ilias A; Drakoulis C; Mimidis K; Ketikoglou I; Manesis E; Mela M; Hatzis G; Dalekos GN;
    J Viral Hepat; 2015 Feb; 22(2):120-7. PubMed ID: 25040685
    [TBL] [Abstract][Full Text] [Related]  

  • 74. External validation of CAGE-B and SAGE-B scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals.
    Ji JH; Park SY; Son WJ; Shin HJ; Lee H; Lee HW; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK
    J Viral Hepat; 2021 Jun; 28(6):951-958. PubMed ID: 33763928
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Utilization of Antiviral Therapy for Patients With Hepatitis B-Related Hepatocellular Carcinoma: A Nationwide Real-World US Study.
    Kudaravalli S; Kam LY; Huang DQ; Cheung R; Nguyen MH
    Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3305-3313.e4. PubMed ID: 37805836
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B.
    Liang LY; Lee HW; Wong VW; Yip TC; Tse YK; Hui VW; Lui GC; Chan HL; Wong GL
    Clin Mol Hepatol; 2021 Jul; 27(3):499-509. PubMed ID: 33631920
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A multi-centre study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy.
    Kim SU; Chon YE; Seo YS; Lee HW; Lee HA; Kim MN; Min IK; Park JY; Kim DY; Ahn SH; Tak WY; Kim BK; Park SY
    J Viral Hepat; 2020 Dec; 27(12):1352-1358. PubMed ID: 32852880
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Risk factors for early-onset and late-onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States.
    Wan DW; Tzimas D; Smith JA; Kim S; Araujo J; David R; Lobach I; Sarpel U
    Am J Gastroenterol; 2011 Nov; 106(11):1994-2000. PubMed ID: 21912436
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prior surveillance and antiviral treatment improve the prognosis of HCC developed in HBV patients in the West.
    Allaire M; El Hajj W; Brichler S; Diallo K; Fanica D; Blaise L; Nkontchou G; Grando V; Arbadi F; Nahon P; Ziol M; Nault JC; Ganne-Carrié N
    Clin Res Hepatol Gastroenterol; 2021 Jan; 45(1):101436. PubMed ID: 32418851
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment.
    Lin MT; Chang KC; Yen YH; Tsai MC; Chen CH; Wang JH; Hsiao CC; Chiu YH; Hu TH
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 3):621-628. PubMed ID: 32718890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.